Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ahlen – page 36

864 clinical trials in Ahlen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ahlen at a glance
864
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

864 trials in Ahlen

Open in trial search

Obesity

Not recruiting

Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriasis

Not recruiting

Study on the Effectiveness of LY4100511 for Adults with Moderate-to-Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY4100511
  • Sponsor:DICE Therapeutics Inc.

Study on the Effects of VHB937 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VHB937
  • Sponsor:Novartis Pharma AG

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Neurodermatitis

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.

Neurodermatitis

Not recruiting

Study on the Effects of Barzolvolimab for Patients with Prurigo Nodularis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Dermatitis atopic

Not recruiting

Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Neurodermatitis

Not recruiting

Study on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Study of Elafibranor in Adults with Primary Biliary Cholangitis Who Don't Respond Well to or Cannot Tolerate Ursodeoxycholic Acid Treatment

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ahlen

What the registry says about research in the country

01 Neoplasms (Cancer) Research

In Ahlen, researchers are conducting two recruiting neoadjuvant studies that target HER2+ early breast cancer and triple-negative early breast cancer. The trials compare novel antibody‑drug conjugates with standard chemotherapy regimens, aiming to improve safety profiles and increase pathological complete response rates.

  • Safety profiling of a trastuzumab‑deruxtecan based regimen
  • Efficacy comparison using 3‑year distant disease‑free survival
  • Assessment of sacituzumab govitecan with or without pembrolizumab
  • Evaluation of pathological complete response as a co‑primary endpoint

The single study center in Ahlen enables close coordination between the investigator team and participating patients, fostering rapid enrollment and data collection for these cutting‑edge breast cancer studies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.